. CTLs recognize viral antigens in the form of peptide fragments of 8 to 10 amino acids which are bound in the grooves of major histocompatibility complex (MHC) class I molecules (5, 20, 33, 49, 51) . These antigenic peptides are derived from nonstructural and structural viral proteins through proteolysis in the cytosolic compartment (15, 46, 56) and are translocated into the endoplasmic reticulum by TAP1/TAP2 transporters (2, 31, 36, 37, 50, 52) , where the peptide, MHC class I molecule, and P-2 microglobulin form a trimolecular complex (48). This complex is then exported to the cell surface through the exocytic pathway (9, 32, 55) for recognition by CD8+ CTL via the T-cell receptor (24, 25) .
CD8+ cytotoxic T lymphocytes (CTL) are crucial in controlling viral infections (14, 57) . CTLs recognize viral antigens in the form of peptide fragments of 8 to 10 amino acids which are bound in the grooves of major histocompatibility complex (MHC) class I molecules (5, 20, 33, 49, 51) . These antigenic peptides are derived from nonstructural and structural viral proteins through proteolysis in the cytosolic compartment (15, 46, 56) and are translocated into the endoplasmic reticulum by TAP1/TAP2 transporters (2, 31, 36, 37, 50, 52) , where the peptide, MHC class I molecule, and P-2 microglobulin form a trimolecular complex (48) . This complex is then exported to the cell surface through the exocytic pathway (9, 32, 55) for recognition by CD8+ CTL via the T-cell receptor (24, 25) .
The identification of viral CTL epitopes that are presented by MHC class I molecules and recognized by the epitopespecific CTL suggests a strategy for designing effective immunogens for the induction of a CD8+ T-cell immune response to provide protection against viral infection (14, 28, 29, 47, 49) . One approach to generating such an immune response utilizes immunization with synthetic peptides corresponding to the CTL epitopes either by themselves or with adjuvants (1, 7, 13, 26, 35, 39) . Another approach has been to express CTL epitopes in virus vectors such as vaccinia virus (3, 4) , either as chimeric proteins (12) or as minigene products (21, 38, 53, 54) . These chimeric proteins or minigene products have been demonstrated to induce CTL responses and, in most cases, provide in vivo protection (12, 28, 54) .
To utilize CTL epitopes as immunogens, it is important to experimentally assess their immunogenic potential by using a vector system most likely to enhance the immunogenicity of the CTL epitopes. In this study, we explored an approach using simian virus 40 (SV40) large tumor antigen (T antigen) as a carrier protein to express CTL epitopes. T antigen, a 94-kDa nuclear protein, immortalizes cells in culture (19, 27, 30, 42) and is highly immunogenic, containing multiple B-cell and T-cell epitopes (43 (43) .
Recently, a library of T antigens in which EcoRI linkers were inserted into the coding region of T antigen at 50-codon intervals between codons 250 and 650 was generated (27) . Two locations in the T antigen (residues 350 and 650) were considered ideal sites for inserting CTL epitopes, since these sites in the protein are not required for immortalization of primary cells in culture (45) . We have translocated an H-2Db_ restricted T-antigen epitope, site I, from its original position between residues 205 and 215 to amino acid positions 350 and 650 of T antigen. In addition, an H-2K"-restricted herpes simplex virus (HSV) type 1 glycoprotein B (gB) CTL epitope, residues 498 to 505 (6), was cloned into the same locations of T antigen (positions 350 and 650). The results show that the translocated SV40 T antigen site I and the HSV gB CTL epitopes in the chimeric T antigens, when expressed in immortalized C57BL/6 (B6) mouse kidney cells, were efficiently processed and were presented by the MHC class I molecules and recognized by the epitope-specific CTL clones.
The chimeric T antigens were generated by using two T-antigen constructs (27) which contain an EcoRI site immediately following codons 350 and 650 of T antigen, pPvu0:E350 and pPvu0:E650, respectively. Oligonucleotide pairs representing two strands of the SV40 T-antigen site I (residues 205 to 215) or the HSV gB (residues 498 to 505) CTL epitope sequence were designed such that when annealed, the small double-stranded fragment would have exposed at each end the sequence 5'-AATT. The annealed oligonucleotides were ligated with the EcoRI-linearized plasmids pPvu0:E350 and pPvu0:E650 by using T4 ligase (Fig. 1A) , and the ligated Two pairs of oligonucleotides representing SV40 T-antigen (Tag) site I (residues 205 to 215) or HSV gB epitope (residues 498 to 505) with EcoRI-compatible ends were synthesized and hybridized. The EcoRIcompatible sequences and adjacent nucleotides added to maintain the correct reading frame are underlined. The oligonucleotide fragments were inserted at the EcoRI site of pPvuO:E350. To remove the original site I sequence within the T-antigen construct which contains the site I sequence at amino acid position 350, the NdeI fragment within the construct was replaced with the corresponding fragment from S1 1-S24 T-antigen mutant, which has a deletion of nucleotides 4443 to 4077 including the site I sequence. The final constructs, p350site I and p350gB, are indicated. Constructs p650site I and p650gB were constructed in a similar manner. N, recognition site for the endonuclease NdeI; E, recognition site for EcoRI. (B) Constructs used in this study and positions of the CTL epitopes. The amino acid sequences of the CTL epitopes are listed in single-letter code. Uppercase letters refer to the CTL epitope amino acid sequences, and lowercase letters represent the flanking amino acids encoded by the EcoRI linker sequence.
products were transfected into competent Escherichia coli DH5o. The recombinant plasmid DNA was purified by the alkaline lysis procedure and analyzed by restriction endonuclease digestion (34) . The restriction endonuclease used to screen recombinant T-antigen constructs containing the site I insert was AsnI, which recognizes an ATTAAT sequence located within the site I epitope sequence, and the restriction endonuclease used to screen recombinants containing the gB epitope insert was EcoRI, because the oligonucleotides were designed such that the EcoRI site would be destroyed upon the insertion. The orientation and authenticity of the inserts were The same amount of protein from each cell lysate was first immunoprecipitated with PAb901 and then blotted onto nitrocellulose membrane and probed with PAb901. Binding of PAb9O1 to T antigen was detected by reacting the blot with goat anti-mouse immunoglobulin G conjugated with horseradish peroxidase and then subjecting the blot to enhanced chemiluminescence treatment (27) . B6/K-pPvuO cells express a wild-type T antigen of about 94 kDa, whereas B6/K-S11-S24 cells express a mutant T antigen with a molecular mass of about 67 kDa as a result of deletion of 124 amino acids.
determined and confirmed by DNA sequencing as described previously (27) . In constructing recombinant T antigens containing a relocated site I epitope, the original site I sequence was removed by fragment exchange with a construct containing the mutant T antigen, S11-S24. S11-S24 produces a T antigen which contains an in-frame deletion from amino acids 127 to 250. Therefore, the S11-S24 T antigen lacks the CTL recognition epitopes site 1 (205 to 215) and site II/III (223 to 231) (41) . A fragment containing the deletion was released from the S11-S24 construct by digestion with NdeI and used to replace the corresponding fragment of the constructs that have the site I sequence inserted at positions 350 and 650 of T antigen (Fig.  IA) .
Expression of chimeric T antigens in primary B6 cells.
Primary adult B6 kidney cells or embryo fibroblasts were immortalized by the wild-type or chimeric SV40 T antigen as described previously (42 (27) with PAb9O1 and were found to contain comparable levels of T antigen. The expression of T antigen in one clonally derived immortalized B6 kidney cell line of each type is shown in Fig.  2 . The lower molecular weight of the chimeric S11-S24 T antigen than of wild-type T antigen is due to the deletion of 124 amino acids. The B6 mouse embryo fibroblasts immortalized by these constructs were found to express similar levels of T antigen (data not shown). Expression and recognition of H-2D"-restricted site I translocated to T-antigen positions 350 and 650. The SV40 large T antigen contains three H-2Db-restricted CTL epitopes, sites I, II/III, and V, which are recognized by the site-specific CTL clones Y-1, Y-2 or Y-3, and Y-5, respectively (10, 40, 41) . Site I is located in the amino-terminal one-third of SV40 T antigen and corresponds to residues 207 to 215 (10 (10) . It was predicted, but not proved, that site I may actually be a 10-mer consisting of residues 206 to 215. The original site I along with the neighboring site II/III sequence within the recombinant T antigens was removed by fragment exchange with a mutant T-antigen sequence, S1I-S24, which has a deletion removing codons 127 to 250. Site II/III has been defined by T-antigen residues 223 to 231 (10) . The processing, presentation, and recognition of the site I in these cell lines were examined by standard 51Cr release assay as described previously (10, Fig. 3) at levels comparable to those in cell lines expressing wild-type T antigen. Again, site II/III was not recognized by the CTL clone, as expected because of the deletion of residues 127 to 250, a segment which includes site II/III (residues 223 to 231). These cells, however, remained susceptible to the lysis by CTL clone Y-5. Similar results were obtained when site I was translocated to T-antigen position 650. These results indicate that the T-antigen site I CTL epitope can be transferred to either position 350 or 650 in T antigen without affecting its processing, presentation, or recognition by the site-specific CTL clone. Expression and recognition of the H-2Kb-restricted HSV gB epitope (498 to 505) transferred to T-antigen positions 350 and 650. Comparison of CTL clone Y-1's recognition of the site I CTL epitope at the original and relocated positions clearly indicated that transfer of this H-2Dh epitope did not affect the efficient processing and presentation of this antigenic determinant. We then tested whether these two positions can be used to express and present an H-2K"-restricted HSV gB CTL recognition epitope at amino acids 498 to 505. This epitope is recognized by HSV CTL clone 2D5 (6) . The data in Fig. 4 show that CTL clone 2D5 can recognize cells immortalized by T antigens containing the gB epitope irrespective of its location at amino acid 350 or 650. These cells were also susceptible to lysis by the CTL clone Y-1 and thus served as positive internal control for the processing of T antigen. It should be noted that the sequences flanking the gB epitope within the recombinant T antigens are different from those of site I transferred to the same locations (Fig. IB) , and neither change in flanking sequences affects the processing, presentation, and recognition of the transferred CTL determinants. Our results show that CTL epitopes restricted by two different restriction elements can be expressed from the same location in T antigen and efficiently presented to epitope-specific CTLs.
The demonstration that CTLs recognize 8-to 10-aminoacid-long peptides presented by the MHC class I molecules has led to efforts to utilize CTL epitopes to induce CTL responses and immune protection against viral infections (28, 29, 35, 49, 51, 54) . Immunization of hosts with synthetic peptides themselves or in combination with adjuvants has been shown to induce the generation of CTL (1, 7, 13, 26, 35, 39) . Alternatively, the CTL epitopes have been presented by using virus vectors, among which vaccinia virus has been used most effectively (3, 4, 12, 28, 53, 54) . In addition, CTL epitopes expressed within heterologous proteins have been shown to be processed, presented, and recognized by epitope-specific CTL (8, 11) . In this study, we investigated the possibility of using SV40 T antigen as a carrier protein to express CTL epitopes. There are several advantages to using T antigen to deliver CTL epitopes. T antigen is a nonstructural nuclear multifunctional protein which is well marked antigenically; as a result, the integrity of the protein in the cells expressing the chimeric protein can be precisely determined by using monoclonal antibodies with defined specificities (43, 45) . The SV40 Tantigen-coding sequence has undergone close scrutiny with respect to the regions that are dispensable for its immortalization function (45) , and multiple cloning sites which can be used for the introduction of CTL epitopes have been inserted into T antigen (27) . T antigen can immortalize primary mouse and other mammalian cells in culture and thus acts as a dominant marker for the selection of transfectants (19, 27, 30, 42 11 -mer, longer than the 10-mer predicted on the basis of the H-2D" binding motif identified by Falk and coworkers (18) . Although the minimum site I determinant includes residues 207 to 215, we have previously shown that an 1 1-mer synthetic peptide corresponding to T-antigen residues 205 to 215 is recognized at a much higher efficiency by CTL clone Y-1 than is the 9-mer synthetic peptide consisting of residues 207 to 215 (10) . It is possible that other locations in T antigen have negative influences on antigen processing.
The H-2Kt-restricted HSV gB epitope, in contrast, matches the MHC binding motif (18, 51 (Sa) . The use of SV40 T antigen as a carrier for foreign CTL epitopes also will allow one to determine the genetic stability of sequences encoding CTL epitopes. 
